#31
|
||||
|
||||
Ñëûøàë åù¸ ïðî òàêîé ñïîñîá ââåäåíèÿ ëåêàðñòâåííûõ ïðåïàðàòîâ: âûïîëíÿåòñÿ ÒÑÖÔÊ â âåðõíåì ñåãìåíòå è â ýòî ìåñòî ïîä êîíüþíêòèâó ââîäèòñÿ ïðåïàðàò. Âðîäå êàê ÷åðåç ïîðàæ¸ííûå ó÷àñòêè ïðîíèêàåò â ÏÊ è âèòðåàëüíóþ ïîëîñòü íàìíîãî áîëüøå ÷åì áåç ÖÔÊ.
Äîëÿ çäðàâîãî ñìûñëà â ýòîì íàâåðíîå åñòü, íî äîêàçàòåëüíûõ èññëåäîâàíèé íå âñòðå÷àë.... Ìîæåò êîìó-òî ïîïàäàëèñü? |
#32
|
|||
|
|||
Öèòàòà:
Àâòîðû: À.Ï. Íåñòåðîâ, Å.À. Åãîðîâ, À.Å. Åãîðîâ, Ä.Â. Êàö. Ïðîâåäåíî áîëåå 7000 îïåðàöèé. Óðîâåíü äîêàçàòåëüíîñòè Ðîññèéñêèé. |
#33
|
|||
|
|||
âî! ýòîò äîêëàä ïîòðÿñ ìåíÿ äî ãëóáèíû äóøè - ãàäîñòü! è äëÿ ÷åãî îíè.....íàäåþñü, âîâñå íå À.Ï., ÍÀÐÓØÀÞÒ ÝÒÎÒ ÁÀÐÜÅÐ!!! Òåïåðü àïîôåîç!!! - äëÿ ïîâûøåíèÿ ýôôåêòà ýìîêñèïèíà!!!! êîòîðûé ïîòîì òóäà "ñòàâÿò" ï/ê!!!
Áåäíûå-áåäíûå áîëüíûå!!! Ïîçîð! |
#34
|
|||
|
|||
Äà, òàì åùå âðîäå ïîìîãàþò â òîì ÷èñëå ïðè ãëàóêîìíîé íåéðîïàòèè, âèäèìî, çà ñ÷åò ãèïîòåíçèâíîãî ýôôåêòà ÖÔÊ, à íå óêîëîâ. È âîïðîñ ïîïóòíî, çà÷åì äî èíúåêöèè 10%!!! - èðèôðèí?
|
#35
|
|||
|
|||
íà ýòî, âèäèìî, òîæå ïàòåíò ïîëó÷èëè - à-ëÿ óìåíüøåíèå ñîñóäèñòîé ðåàêöèè!
ïðî öèêëîäåñòðóêöèþ ïðîòèâ íè÷åãî íå èìåþ, íî â ýòîì ñëó÷àå íå î òîì øëà ðå÷ü - ÿ, ÷åñòíî ãîâîðÿ, ïîäóìàëà ñíà÷àëà, ÷òî ýòî ó ìåíÿ ãàëëþöèíàöèè - ãîðå÷ü ñìåíèëàñü õîõîòîì - íî!!! ñàìîå îãîð÷èòåëüíå - ðÿäîì ñèäÿùèå øèêàëè, ò.ê. ÿ ìåøàþ èì çàïèñûâàòü ïàðàìåòðû ØÅÄÅÂÐÀ äëÿ !!! âîïëîùåíèÿ â æèçíü â ãîðîäàõ è ñåëàõ. |
#36
|
|||
|
|||
Öèòàòà:
|
#37
|
|||
|
|||
Íåò. Âñå ðàâíî íå ìîãó ñîãëàñèòñÿ ñ òåì ÷òî ñ/ê ââåäåíèå àâàñòèíà íåîáõîäèìî. Äàæå â ñòàòüå ïðåäñòàâëåííîé ainakoz àâòîðû îòìå÷àþò áîëüøóþ êîíöåíòðàöèþ ïðåïàðàòà â êðîâè, ÷åì â ïåðåäíåé êàìåðå. Êàê ìèíèìóì â ïåðåäíþþ êàìåðó ïðåïàðàò ïîïàäàåò õóæå ÷åì â êðîâü. Òàê ìîæåò ëó÷øå ââåñòè åãî ñðàçó â êðîâü, òåì áîëåå ÷òî ïðè â/â ââåäåíèè ìû íå îãðàíè÷åíû äîçîé. Ìîæíî ââåñòè õîòü âåñü ôëàêîí (100 èëè 400 ìã).
Íàøåë àáñòðàêò, ãäå åñòü êîíêðåòíûå öèôðû êîíöåíòðàöèè àâàñòèíà â ïëàçìå êðîâè è âî âëàãå ïåðåäíåé êàìåðû âòîðîãî ãëàçà (ïðàâäà ïðåïàðàò ââîäèëñÿ â ñòåêëîâèäíîå òåëî, íî ìíå èíòåðåñíà ýôôåêòèâíîñòü ïîïàäàíèÿ áåâàöèçóìàáà â ïåðåäíþþ êàìåðó ïàðíîãî ãëàçà èç êðîâè). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Ñîñòàâèì ïðîïîðöèþ è óçíàåì, ÷òî äëÿ äîñòèæåíèÿ êîíöåíòðàöèè â ïåðåäíåé êàìåðå 70 íãð/ìë (èç ñòàòüè ainakoz-à) â ïëàçìå êðîâè äîëæíî áûòü 7,86 ìêãð/ìë. Çíàÿ êàæóùèéñÿ îáúåì ïåðåðàñïðåäåëåíèÿ àâàñòèíà ïðè â/â ââåäåíèè ó ÷åëîâåêà(3 ëèòðà), íàõîäèì, ÷òî äëÿ ïîëó÷åíèÿ òàêîé êîíöåíòðàöèè â ïëàçìå êðîâè ÷åëîâåêó íàäî ââåñòè 23,6 ìã ïðåïàðàòà (÷åòâåðòü ñàìîãî ìàëåíüêîãî ôëàêîíà). Òàê çà÷åì îãîðîä ãîðîäèòü? Äà â/â íóæíî ââåñòè áîëüøå ÷åì ïðè ñ/ê ââåäåíèè, íî ýòà äîçà çíà÷èòåëüíî ìåíüøå íàçíà÷àåìîé ïðè êîëîðåêòàëüíîì ðàêå! Òàì ìèíèìóì 5ìã/êã, ò.å 300ìã äëÿ ïàöèåíòà âåñîì 60êã! |
|
#38
|
||||
|
||||
|
#39
|
|||
|
|||
Öèòàòà:
Íà ïðîøåäøåé åâðîðåòèíå áûëè ïðåäñòàâëåíû äàííûå ñèñòåìíûõ(ñîñóäèñòûõ) îñëîæíåíèé(òî÷íåå ëåòàëüíûõ èñõîäîâ â ðåçóëüòàòå èíôàðêòîâ è òä) ó ïàöèåíòîâ, ïîëó÷àâøèõ ýíäîâèòðåàëüíî àâàñòèí è ëþöåíòèñ. Òî÷íûå öèôðû ñåé÷àñ íå íàéäó, íî â ãðóïïå àâàñòèíà îíè èìåëè ìåñòî â îòëè÷èå îò ëþöåíòèñà. ×òîæ áóäåò, åñëè ìû âñåì â/â êîëîòü áóäåì? À âåäü ïðèòåíäåíòû íà àíòè-VEGF òåðàïèþ àïðèîðè ëþäè ñ ïàòîëîãèåé ÑÑÑ, ÷òî ïðè äèàáåòå, ÷òî ïðè ÂÌÄ, íó ðàçâå ÷òî ìèîïîâ ìîæíî çäîðîâûõ ïîèñêàòü...Ïðè îíêîëîãèè öåëü - æèçíü ÷åëîâåêó ñïàñòè ëþáîé öåíîé, à ìû ñ âàìè äîëæíû äóìàòü è î áåçîïàñíîñòè è î êà÷åñòâå æèçíè ïàöèåíòà. |
#40
|
|||
|
|||
Öèòàòà:
|
#41
|
|||
|
|||
Öèòàòà:
ß òàê ïîíèìàþ,÷òî Âû ââîäèëè íåðàçâåäåííûé ïðåïàðàò? Åñëè òàê, òî 0,5 ìë àâàñòèíà, ýòî 12,5 ìã ïðåïàðàòà (100ìã/4 ìë), ÿ æå ïðåäëàãàþ ââîäèòü âíóòðèâåííî ïðèìåðíî 25ìã - ýòî 1.0ìë. Ñ÷èòàéòå äîçà àíàëîãè÷íà ñóáòåíîíîâîìó ââåäåíèþ â îáà ãëàçà! Ñîìíåâàþñü ÷òî ÷àñòîòà îñëîæíåíèé ïðè ýòîì áóäåò çíà÷èòåëüíî âûøå! |
#42
|
|||
|
|||
Öèòàòà:
From Medscape Medical News Bevacizumab and Ranibizumab Both Safe for Age-Related Macular Degeneration Emma Hitt, PhD Authors and Disclosures Physician Rating: ( 3 Votes ) Rate This Article: October 12, 2010 — Newer therapies for age-related macular degeneration (AMD), including bevacizumab and ranibizumab, do not appear to be associated with increased risk for mortality, myocardial infarction, bleeding, or stroke compared with photodynamic therapy or pegaptanib, new research suggests. Lesley H. Curtis, PhD, from the Duke Clinical Research Institute, in Durham, North Carolina, and colleagues reported their findings in the October issue of the Archives of Ophthalmology. According to the researchers, bevacizumab is a full-length antibody, whereas ranibizumab is an antibody fragment developed specifically for use in AMD. "Despite the regulatory approval of ranibizumab, off-label use of bevacizumab continues, likely because of the cost difference ($1950 per dose of ranibizumab vs $30 per dose of bevacizumab)," the authors note. In colorectal and other cancers, bevacizumab is used at a 150-fold stronger systemic dose in combination with chemotherapy and is associated with an increased risk for thromboembolic and other adverse events; however, the relative safety of bevacizumab at a reduced dose and of ranibizumab is unknown. In the current study, the researchers performed a retrospective analysis of 146,942 Medicare beneficiaries who made claims for AMD treatment from January 1, 2005, to December 31, 2006. Patients were classified into 4 groups based on treatment, including photodynamic therapy (the active control), intravitreous pegaptanib octasodium, bevacizumab, or ranibizumab. The risk for death was significantly lower with ranibizumab therapy than with photodynamic therapy (hazard ratio [HR], 0.85; 99% confidence interval [CI], 0.75 - 0.95) or pegaptanib (HR, 0.84; 99% CI, 0.74 - 0.95). In addition, the risk for myocardial infarction was significantly lower with ranibizumab use vs photodynamic therapy (HR, 0.73; 99% CI, 0.58 - 0.92). Mortality and myocardial infarction risk were comparable between bevacizumab and the other therapies, and there was no statistically significant relationship between treatment group and bleeding events or stroke. Limitations of the trial include lack of randomization, no untreated control group, and no information on comorbid conditions. "We found no evidence of increased risks of mortality, myocardial infarction, bleeding, or stroke among Medicare beneficiaries who received intravitreous ranibizumab or bevacizumab for neovascular [AMD]," Dr. Curtis and colleagues conclude. According to the researchers, neither photodynamic therapy nor pegaptanib use was associated with serious adverse systemic effects in randomized controlled trials, but the risk for systemic adverse events in the current study was lowest with ranibizumab use. An explanation for this may include the fact that patients receiving ranibizumab may have been healthier. "Selective treatment of higher-risk patients with ranibizumab instead of bevacizumab is plausible given concerns about the increased risks of thromboembolic events associated with intravenous bevacizumab," the researchers note. "The findings of this study help to reassure vitreoretinal specialists who treat macular degeneration that intravitreal bevacizumab does not increase risk of systemic complications when compared to previous therapies, such as photodynamic therapy and pegaptanib," said independent commentator Manju Subramanian, MD, from the Boston University School of Medicine, in Massachusetts. According to Dr. Subramanian, these findings are not too surprising, given that several smaller retrospective studies have corroborated these results. She added that most clinicians will now likely put the question of safety to rest, she told Medscape Medical News. "The question of efficacy still needs further investigation, and large clinical trials are currently underway to address this question." |
#43
|
|||
|
|||
Öèòàòà:
|
#44
|
|||
|
|||
Öèòàòà:
Êðîìå òîãî, âû ïðåäëàãàåòå ñèñòåìíîå ââåäåíèå 1 ðàç, èëè ñ ðåãóëÿðíîñòüþ, ðåêîìåíäîâàííîé äëÿ ëå÷åíèÿ õíâ? Î ÷åì âåäåì ðàçãîâîð? Âû ðåàëüíî ñ÷èòàåòå åãî íåîáõîäèìûì? Òîãäà óæ, áóäüòå ëþáåçíû, êîëü âëÿïàëèñü â äèñêóññèþ, - ïîðîéòå ññûëêè îá îñëîæíåíèÿõ ïðè äð. çàáîëåâàíèÿõ ïðè ââåäåíèè â/â - îá ýôôåêòå áóìåðàíãà, î öåëåñîîáðàçíîñòè êîìáèíàöèè òåðàïèè ñ ýðèòðîïîýòèíîì, î ïðîô. âîñïàëèòåëüíûõ çàáîëåâàíèé è ñðîêàõ íîðìàëèçàöèè ãåìîïîýçà. È ìû ñî÷òåì, ÷òî âðåìÿ, ïîðòà÷åííîå íà ïèñàíèå ïîñòîâ â ýòîé òåìå, ïîòðà÷åíî íå çðÿ. Ïëèç... ñêàæåì ñïàñèáî. |
#45
|
||||
|
||||
Rameyka!!! Âîñõèù¸í!!! Ïðåäûäóùåå ñîîáùåíèå îäîáðÿåòñÿ âïëîòü äî ÏÎÐßÄÊÀ ÑËΠ ÏÐÅÄËÎÆÅÍÈÈ!!! Èñêàë ÷òî áû îòöèòèðîâàòü äëÿ îäîáðåíèÿ, ïðèõîäèòñÿ öèòèðîâàòü îò ïåðâîãî äî ïîñëåäíåãî çíàêà ïðåïèíàíèÿ.
Êîðî÷å ÎÄÎÁÐÈË! +1000! |